Actively Recruiting
Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements for PCOS, POI, and Fertility Assessment
Led by Chinese University of Hong Kong · Updated on 2025-03-27
300
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the relationship between Anti-Müllerian hormone (AMH) levels and conditions such as polycystic ovarian syndrome (PCOS), premature ovarian insufficiency (POI), and fertility. This prospective observational study aims to understand how AMH can help diagnose PCOS, manage POI, and predict reproductive outcomes in women undergoing assisted reproductive technology (ART) treatment. The study also looks at how AMH levels correlate with other markers like follicle-stimulating hormone (FSH) and antral follicle count (AFC). The research is sponsored by the Chinese University of Hong Kong and runs from 2022 to 2026. Participants include women attending clinics for PCOS and POI management and those receiving ART treatment. Routine blood tests will measure serum AMH, FSH, luteinizing hormone (LH), estradiol, and AFC through transvaginal ultrasound before treatment begins. Remaining serum samples from these tests will be stored and analyzed for the study. The study will also evaluate the types and doses of gonadotropins used for ovarian stimulation during ART. During the study, participants will undergo blood tests and ultrasounds to assess ovarian reserve and hormone levels. Data collected includes AMH levels within 1 to 2 months after recruitment, hormone levels on the first day of ovarian stimulation, total gonadotropin dose, number of oocytes retrieved, clinical pregnancy rates, and live birth rates. Researchers will analyze these results to explore AMH's predictive value for reproductive outcomes. The total participation spans from initial recruitment through pregnancy outcomes for those undergoing ART.
CONDITIONS
Brief Title
Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women attending the Paediatric and Adolescent Gynaecological Clinic or Gynaecological Endocrine Clinic for management of PCOS or POI
- Women attending the Assisted Reproductive Technology (ART) Unit for ART treatment
- Female participants aged 10 to less than 45 years
You will not qualify if you...
- Women younger than 10 years or 45 years and older
- Women with current or past diseases affecting gonadotropin or sex steroid hormone secretion, clearance, or excretion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 months after recruitment
Participants undergo blood tests for AMH, hormonal profiles, and transvaginal ultrasound for antral follicle count to assess ovarian reserve and diagnose PCOS or POI.
1 to 2 visits depending on assessment needs
Duration - Up to 4 years
Participants who undergo routine care for PCOS, POI, or assisted reproductive technology (ART) treatment are observed with ongoing measurements collected from medical records and follow-up evaluations.
Visits as part of routine clinical care
Trial Site Locations
Total: 1 location
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
W
WING IU LI
P
PUI WAH JACQUELINE CHUNG
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here